{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:43:52Z","timestamp":1768002232482,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.urolonc.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:51:27Z","timestamp":1603457487000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Rosa","family":"Nadal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.10.004_bib0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0002","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0003","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0004","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.ju.0000090967.08622.33","article-title":"Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis","volume":"171","author":"Winquist","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists","volume":"354","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0007","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0008","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0009","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1590\/S1677-55382010000500025","article-title":"Prevention and management of complications following radical cystectomy for bladder cancer","volume":"36","author":"Bohle","year":"2010","journal-title":"Int Braz J Urol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0011","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41416-018-0084-z","article-title":"Health-related quality of life after treatment for bladder cancer in England","volume":"118","author":"Mason","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.12121","article-title":"Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes","volume":"113","author":"Lee","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0013","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.eururo.2012.01.039","article-title":"Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire","volume":"61","author":"Burger","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0014","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0015","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ijrobp.2016.11.056","article-title":"Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"97","author":"Vashistha","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0016","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4546","article-title":"KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)\u2014 Updated response and survival results","volume":"37","author":"O'Donnell","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"38","author":"Black","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2020.10.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.442","article-title":"DCN, SUO Clinical Trials Consortium: Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial","volume":"38","author":"Boorjian","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0024","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med."},{"issue":"suppl_8","key":"10.1016\/j.urolonc.2020.10.004_bib0026","article-title":"Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)","volume":"29","author":"van Dijk","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0027","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.507","article-title":"Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2","volume":"38","author":"Wei","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0029","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clgc.2012.10.001","article-title":"Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer","volume":"11","author":"Galsky","year":"2013","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.499","article-title":"Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin\/gemcitabine (Cis\/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): preplanned interim analysis of a single-arm phase II trial (SAKK 06\/17)","volume":"38","author":"Cathomas","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of Durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 Open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0034","article-title":"A Phase IB\/2 Study of Neoadjuvant Pembrolizumb(PEMBRO) and chemotherapy for locally advanced Urothelial Cancer (UC)","volume":"29","author":"Holmes","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0035","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2020.38.15_suppl.5019","article-title":"Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188","volume":"38","author":"Kaimakliotis","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0036","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2014.11.003","article-title":"Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer","volume":"29","author":"McConkey","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0037","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2217\/fon-2020-0215","article-title":"Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication","volume":"16","author":"Lamberti","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0038","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.4501","article-title":"Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma","volume":"32","author":"Apolo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies","volume":"39","author":"Meenal Datta","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.urolonc.2020.10.004_bib0041","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bju.14736","article-title":"Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients","volume":"124","author":"Kijima","year":"2019","journal-title":"BJU Int."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0042","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0043","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0044","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13014-016-0618-6","article-title":"Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients","volume":"11","author":"Lutkenhaus","year":"2016","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1535-7163.MCT-18-0986","article-title":"PD-1\/PD-L1 Immune checkpoint inhibition with radiation in bladder cancer: in situ and abscopal effects","volume":"19","author":"Rompre-Brodeur","year":"2020","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0046","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1111\/j.1464-410X.2011.10792.x","article-title":"Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy","volume":"110","author":"Yafi","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0047","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5093","article-title":"Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992","volume":"38","author":"Balar","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0048","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.urolonc.2020.10.004_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.513","article-title":"Concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of bladder (DUART): Btcrc-GU15-023","volume":"38","author":"Joshi","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:55Z","timestamp":1761042355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920304774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1078143920304774"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.10.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}